(Q30919484)

English

Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Carbonic anhydrase-IX score is a novel biomarker that predicts recurrence and survival for high-risk, nonmetastatic renal cell carcinoma: Data from the phase III ARISER clinical trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

0 references

phase III clinical trial

0 references

renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Karim Chamie

1

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Pia Klöpfer

2

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Paul Bevan

3

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Stephan Störkel

4

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Jonathan Said

5

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Barbara Fall

6

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Arie S Belldegrun

7

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Allan J Pantuck

8

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

publication date

29 March 2015

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Urologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

204.e25-33

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.013

7 January 2021

Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.013

7 January 2021

Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.013

7 January 2021

Using protein expressions to predict survival in clear cell renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.013

7 January 2021

Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.013

7 January 2021

Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.013

7 January 2021

Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.013

7 January 2021

Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.013

7 January 2021

Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.013

7 January 2021

Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.013

7 January 2021

131 I-cG250 monoclonal antibody immunoscintigraphy versus [18 F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.013

7 January 2021

Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.013

7 January 2021

Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.013

7 January 2021

Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2015.02.013

7 January 2021

Identifiers

10.1016/J.UROLONC.2015.02.013

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30919484&oldid=1965817806"